Examination of HER3 targeting in cancer using monoclonal antibodies

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• The human EGF receptor (HER/EGFR) family, including EGFR, HER2, and HER3, are critical targets in cancer therapy.
• HER3's role in cancer drug resistance and as a dimerization partner for EGFR and HER2 has been underestimated.
• Targeting HER3 presents a potential therapeutic strategy, despite challenges like low expression and impaired kinase activity.

Purpose of the Study:

• To generate and evaluate monoclonal antibodies targeting HER3.
• To identify an antibody with potent anti-tumor activity against pancreatic cancer.
• To explore the therapeutic potential of targeting HER3 in cancer treatment.

Main Methods:

• Generation of multiple monoclonal antibodies against HER3.
• In vitro assessment of antibody functions: HER3 degradation, downstream signaling inhibition, cell growth inhibition, and immune cell recruitment.
• In vivo evaluation of the most potent antibody in animal models of pancreatic cancer.

Main Results:

• Selection of a lead monoclonal antibody against HER3 based on its functional properties.
• Demonstration of potent inhibition of pancreatic cancer cell growth in animal models by the selected anti-HER3 antibody.
• Evidence suggesting that anti-HER3 antibodies can overcome drug resistance by intercepting specific cellular interactions.

Conclusions:

• Monoclonal antibodies targeting HER3 are a promising therapeutic approach for cancer.
• Targeting HER3, particularly its autocrine and stroma-tumor interactions, may effectively inhibit tumor growth and overcome drug resistance.
• This strategy holds potential for treating various cancers, analogous to existing anti-EGFR therapies in colorectal cancer.